clinical trial · NCT05701774
Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome
Soleno Therapeutics, Inc.·phase3·active not recruiting·n = 83
Prader-Willi SyndromeDCCR
brief summary
The purpose of this is study is to evaluate the long-term safety of DCCR (diazoxide choline) extended-release tablets) in patients with Prader-Willi syndrome.
started
Jan 31, 2023
primary completion
Jun 1, 2028
completion
Jun 1, 2028
last updated
Apr 2, 2025
official title
An Open-Label Study of DCCR (Diazoxide Choline) Extended-Release Tablets in Patients With Prader-Willi Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol